Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000892804 | SCV001036705 | likely benign | Drash syndrome; Frasier syndrome; Wilms tumor 1; 11p partial monosomy syndrome | 2023-10-24 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002492615 | SCV002796015 | likely benign | Aniridia 1; Drash syndrome; Frasier syndrome; Meacham syndrome; Mesothelioma, malignant; Nephrotic syndrome, type 4; Wilms tumor 1; 11p partial monosomy syndrome | 2021-10-04 | criteria provided, single submitter | clinical testing | |
Gene |
RCV003162657 | SCV003915010 | uncertain significance | not provided | 2022-10-07 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Observed in an individual with congenital nephrotic syndrome (Joshi et al., 2021); This variant is associated with the following publications: (PMID: 33980730, 8486616) |
Blueprint Genetics | RCV000157583 | SCV000207329 | uncertain significance | Proteinuria | 2014-09-15 | no assertion criteria provided | clinical testing | |
Prevention |
RCV004551354 | SCV004789381 | likely benign | WT1-related disorder | 2022-03-07 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |